The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …

Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) are an important
endpoint in multinational clinical treatment trials, but the observed event rate is often lower …

Background COPD is a leading cause of death and disability. COPD therapy goals include
reducing exacerbations and improving symptom control. Single-inhaler triple therapy (SITT) …

Importance Clinical guidelines on chronic obstructive pulmonary disease (COPD)
recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long …

Rationale: Randomized controlled trials only include a subset of patients with chronic
obstructive pulmonary disease (COPD) fulfilling strict inclusion criteria. Thus, most patients …

Background Whether risk of exacerbations of chronic obstructive pulmonary disease
(COPD) is influenced by severity of symptoms and maintenance treatment is unclear …

Background and objective Non‐invasive ventilation (NIV) is part of the standard of care for
hypercapnic respiratory failure secondary to COPD, but may be poorly tolerated. Preliminary …

Background Patients with severe asthma not meeting the strict trial eligibility criteria for
mepolizumab are now routinely treated with this biological in clinical practice, but it remains …

Introduction While inhaled corticosteroids (ICS) may increase pneumonia risk in patients
with chronic obstructive pulmonary disease (COPD), the impact of ICS on pneumonia …

Acute exacerbations are largely responsible for the poor outcomes characterising COPD,
the third leading cause of death globally and associated with a significant disability and …